AI-Driven Drug Discovery Accelerates with Focus on Molecular Interactions for COVID-19 Antivirals
March 2024
Recent advancements in artificial intelligence and computational chemistry are revolutionizing drug discovery, particularly in the wake of the COVID-19 pandemic. Researchers are using AI algorithms to rapidly screen vast libraries of compounds and predict their binding affinities to viral proteins. This process heavily relies on accurately modeling the intermolecular forces (hydrogen bonding, van der Waals interactions, electrostatic forces) between potential drug molecules and target viral enzymes (like the main protease of SARS-CoV-2). By understanding and optimizing these molecular interactions, scientists can design more effective and selective antiviral drugs, significantly reducing the time and cost associated with traditional drug development. This highlights the practical, life-saving application of IMFs.
UPSC Angle: UPSC can ask about the role of AI in drug discovery, linking it to fundamental chemical principles like intermolecular forces. Questions might focus on how specific IMFs contribute to drug-receptor binding, or the challenges in designing drugs that effectively target viral proteins while minimizing off-target effects, all rooted in molecular interactions.